Literature DB >> 12687400

Prostatitis: the role of antibiotic treatment.

F M E Wagenlehner1, K G Naber.   

Abstract

The prostatitis syndrome is commonly found in urologic practice and is classified according to the NIDDK/NIH, in which bacterial prostatitis (acute and chronic) is distinguished from chronic pelvic pain syndrome (CPPS). In acute bacterial prostatitis (NIH category I), antibiotic treatment is mandatory and successful in most cases. In chronic bacterial prostatitis (NIH category II), antibiotics must be selected according to suitable pharmacokinetic/pharmacodynamic parameters and therapy should be prolonged. The success varies according to the etiologic pathogen and the course of the infection. In inflammatory CPPS (NIH category IIIA) antibiotics can be tried initially and continued, if symptoms improve. There is no consensus regarding the role of antibiotic treatment in patients with non-inflammatory CPPS (NIH category IIIB) and asymptomatic prostatitis (NIH category IV).

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12687400     DOI: 10.1007/s00345-003-0333-4

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  21 in total

Review 1.  Pharmacological modulation of myocardial depressant factor as a mediator of circulatory shock.

Authors:  A M Lefer
Journal:  J Chemother       Date:  1989-07       Impact factor: 1.714

2.  Transrectal ultrasonography directed intraprostatic injection of gentamycin-xylocaine in the management of the benign painful prostate syndrome. A report of a 5 year clinical study of 75 patients.

Authors:  J S Mayersak
Journal:  Int Surg       Date:  1998 Oct-Dec

3.  The National Institutes of Health chronic prostatitis symptom index: development and validation of a new outcome measure. Chronic Prostatitis Collaborative Research Network.

Authors:  M S Litwin; M McNaughton-Collins; F J Fowler; J C Nickel; E A Calhoun; M A Pontari; R B Alexander; J T Farrar; M P O'Leary
Journal:  J Urol       Date:  1999-08       Impact factor: 7.450

4.  Lomefloxacin versus ciprofloxacin in the treatment of chronic bacterial prostatitis.

Authors:  Kurt G Naber
Journal:  Int J Antimicrob Agents       Date:  2002-07       Impact factor: 5.283

5.  Treatment of chronic bacterial prostatitis with ciprofloxacin. Results of a one-year follow-up study.

Authors:  W Weidner; H G Schiefer; A Dalhoff
Journal:  Am J Med       Date:  1987-04-27       Impact factor: 4.965

Review 6.  The role of antibiotics in the treatment of chronic prostatitis: a consensus statement.

Authors:  T E Bjerklund Johansen; R N Grüneberg; J Guibert; A Hofstetter; B Lobel; K G Naber; J Palou Redorta; P J van Cangh
Journal:  Eur Urol       Date:  1998-12       Impact factor: 20.096

7.  Diagnosis and treatment of 409 patients with prostatitis syndromes.

Authors:  J J de la Rosette; M R Hubregtse; E J Meuleman; M V Stolk-Engelaar; F M Debruyne
Journal:  Urology       Date:  1993-04       Impact factor: 2.649

8.  Treatment of chronic prostatitis: intraprostatic antibiotic injections under echography control.

Authors:  J F Jiménez-Cruz; F B Tormo; J G Gómez
Journal:  J Urol       Date:  1988-05       Impact factor: 7.450

9.  Cefuroxime axetil versus ofloxacin for short-term therapy of acute uncomplicated lower urinary tract infections in women.

Authors:  K G Naber; E M Koch
Journal:  Infection       Date:  1993 Jan-Feb       Impact factor: 3.553

10.  Seminal fluid findings in men with nonbacterial prostatitis and prostatodynia.

Authors:  J N Krieger; R E Berger; S O Ross; I Rothman; C H Muller
Journal:  J Androl       Date:  1996 May-Jun
View more
  2 in total

Review 1.  Gut microbiome and chronic prostatitis/chronic pelvic pain syndrome.

Authors:  Hans C Arora; Charis Eng; Daniel A Shoskes
Journal:  Ann Transl Med       Date:  2017-01

Review 2.  Dealing with non-cancerous findings on prostate biopsy.

Authors:  Timothy C Brand; Gregory P Thibault; Joseph W Basler
Journal:  Curr Urol Rep       Date:  2006-05       Impact factor: 2.862

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.